[8-K] Unicycive Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Insights

Regulatory Compliance Analyst

Restored Nasdaq price compliance removes delisting overhang, improving liquidity and financing optionality.

Item 8.01 reports that Unicycive has regained compliance with Nasdaq Rule 5550(a)(2), which requires a minimum $1 bid price. Nasdaq has closed the matter, according to the filing.

Why it matters: An unresolved deficiency could have led to delisting, migration to an over-the-counter venue, reduced institutional participation, and higher capital costs. Compliance means those structural threats are lifted without a reverse split, indicating the share price has met the rule—typically ten consecutive trading days above $1.

Operational effects: The company keeps uninterrupted access to Nasdaq’s liquidity pool and maintains eligibility to use existing shelf registration statements. Continued national-exchange status also supports negotiations with partners whose agreements may require such listing.

No immediate financial metrics change, but removal of listing uncertainty is incrementally positive for shareholders and creditors.

false 0001766140 0001766140 2025-07-07 2025-07-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 7, 2025

Unicycive Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40582		81-3638692
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		IRS Employer Identification No.)

4300 El Camino Real, Suite 210

Los Alto, CA 94022

(Address of principal executive offices)

Registrant’s telephone number, including area code: (650) 351-4495

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock		UNCY		Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 8, 2025, Unicycive Therapeutics, Inc. issued a press release announcing it has regained compliance with the Nasdaq Stock Market continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Press Release of Unicycive Therapeutics, Inc. dated July 8, 2025.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 8, 2025

	UNICYCIVE THERAPEUTICS, INC.
	By:	/s/ Shalabh Gupta
		Shalabh Gupta
		Chief Executive Officer

2